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Human neutrophils incorporate and metabolize platelet-activating factor (PAF). We dissociated these events from PAF 
binding to its receptors. Cells were pretreated with either pronase, a PAF antagonist (L652731), or excess PAF. This 
reduced PAF receptor numbers by 70 to almost 100% but had no comparable effect upon the neutrophil's ability to meta- 
bolize PAF. Furthermore, HL-60 cells efficiently metabolized, but did not specifically bind, PAF. Thus, PAF receptor 
availability did not correlate with PAF metabolic apacity and we conclude that myelogenous tissues can process this 
bioactive ligand by a receptor-independent pathway. 
Platelet-activating factor; Receptor; Phospholipid metabolism; (Polymorphonuclear leukocyte, HL-60 promyelocyte) 
1. INTRODUCTION 
Many cellular stimuli bind with plasmalemmal 
receptors to form complexes that not only sti- 
mulate function but also trigger their own inter- 
nalization. The complexes commonly internalize in 
vesicles which traverse cytosol and merge with 
Golgi/granules where entrapped ligand is depo- 
sited and soon degraded [1]. PAF may be processed 
by such a receptor-mediated endocytotic pathway. 
This unique 1-O-alkyl-2-acetyl-GPC uses plasma 
membrane receptors to activate diverse cell types. 
These same target cells deacetylate PAF, acylate 
the 1-O-alkyl-2-1yso-GPC intermediate, and store 
the final product, 1-O-alkyl-2-acyl-GPC, in 
Golgi/granules [2,3]. Furthermore, Lachachi et al. 
[4] reported that a PAF antagonist almost com- 
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pletely blocked rabbit platelet metabolism of PAF. 
Homma et al. [5], however, found that other an- 
tagonists lacked this effect; the authors suggested 
that PAF bypasses rabbit platelet receptors to 
reach intracellular metabolizing enzymes. This 
controversy bears not only on the existence of a 
novel, stimulus processing pathway but also on 
therapeutic issues. In particular, antagonists, by 
blocking receptor-mediated metabolism, could 
worsen acute diseases (e.g. thrombosis, allergy, in- 
flammation, and shock) involving the pathologic 
actions of endogenously formed PAF. According- 
ly, we here employ several techniques to evaluate 
the receptor dependency of PAG metabolism in 
myelogenous tissues. 
2. MATERIALS AND METHODS 
2.1. Reagents and buffers 
[3H]PAF and l-O-[3H]hexadecyl-2-1yso-GPC (56 Ci/mmol), 
PAF, l-O-alkyl-2-1yso-GPC, 1,2-diacyl-GPC, L652731, deli- 
pidated BSA, silicone oil, TLC plates, pronase and modified 
Hanks' buffer were obtained as in [3,6,7]. PAF and analogs 
were taken up in buffer containing 2.5 mg/ml BSA; 50/~1 of this 
was added to 950 ~1 cell suspension. 
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2.2. Binding 
PMN were isolated from normal human donors [3]; HL-60 
cells were purchased (American Type Culture Collection, 
Rockville, MD). We conducted [3H]PAF binding at 4°C using 
centrifugation through silicone oil to separate cells from 
medium [6]. 
2.3. Metabolism 
Cells were incubated inbuffer for 20 min at 37°C and treated 
with [3H]PAF, _+ unlabelled PAF, for the indicated intervals. 
Reactions were stopped by adding 1.4 vols methanol/chloro- 
form (2: 1, v/v). Chloroform layers were removed, 0.7 vol. 
chloroform added to reaction mixtures, and the second chlo- 
roform layers isolated. Pooled chloroform layers were applied 
to TLC plates (preheated for 3 h at 180°C) and developed in 
chloroform/methanol/glacial acetic acid/water (50: 25 : 8:4, 
v/v). Plates were scraped (5 mm zones) and counted for tritium. 
Material migrating with lyso-PAF (Rf = 0.25), PAF 
(Rf = 0.35), and 1,2-diacyl-GPC (the standard for 1-O- 
alkyl-2-acyl-GPC; Rf = 0.6) was calculated as percentage of
total recovered radiolabel (recovery > 92°7o of that added to 
cells). The percentage of added PAF metabolized after 0, 2.5, 5, 
and 10 min was fitted to a straight line by the method of least 
squares. These lines were used to estimate the average rate of 
PAF metabolism during the initial 10 min of incubation. 
3. RESULTS AND DISCUSSION 
PMN and HL-60 promyelocytes converted 
[3H]PAF to 1-O-[3H]hexadecyl-2-1yso-GPC and 
1-O-[3H]hexadecyl-2-acyl-GPC (the latter always 
represented > 80°70 of formed product). This con- 
version increased with time and cell concentration 
(fig. 1, upper panels). Its initial rate in PMN, but 
not HL-60 cells, also increased with PAF concen- 
trations up to 6000 pM, above which metabolism 
slowed in both cell types (fig. 1, lower panels). We 
emphasize that our results are given as the percen- 
tage of added PAF converted to TLC-identified 
products. The absolute mass of PAF metabolized 
(and products formed) approached a maximum 
of - 1 pmol/107 PMN per min (60000 mole- 
cules/PMN per min) at 2/zM PAF. 
Three types of experiments evaluated the recep- 
tor requirements for PAF metabolism. First, 
HL-60 cells did not specifically bind [3H]PAF 
(fig.2D). We examined binding to 2.5 x 10 7 
HL-60 cells under conditions in which binding to 
2.5 x 105 PMN was readily detected. Relative to 
PMN, therefore, promyelocytes have less than 1070 
of the specific binding capacity but more than 
4-fold greater metabolic apacity (cf. upper panels 
in fig.l) for PAF. Second, 10 7 PMN incubated 
with 200 fmol 1-O-[3H]hexadecyl-2-1yso-GPC 
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Fig. 1. Cellular metabolism of PAF. Upper panels: the indicated 
number (x 106/ml) of PMN or HL-60 cells were incubated with 
200 pM [3H]PAF for the indicated period. Lower left panel: 107 
PMN/ml were incubated with varying amounts of [3H]PAF + 
PAF (radiolabeled and unlabeled ligand added separately but 
simultaneously). Lower right panel: 5 × 106 ( ) or 
1.25 × 10 e (---)  HL-60 cells were similarly incubated with 
radiolabeled and unlabeled iigand. Results are presented as the 
percentage of added ligand metabolized at the indicated time 
(upper panels) or the average percentage of added ligand 
metabolized per 10 min (see Section 2) (lower panels) for PMN 
from 4-11 different donors or for HL-60 cells obtained on two 
separate occasions. 
formed 60, 80, 100, 140, and 160 fmol 1-O- 
[3H]hexadecyl-2-acyl-GPC in 2.5, 5, 10, 20, and 40 
min, respectively. Under the same conditions, 
PMN converted 200 fmol [3H]PAF to 30, 60, 110, 
150, and 160 fmol products (lyso + acylated 
derivatives) at these times. PMN therefore meta- 
bolize [3H]PAF and its lyso analog at similar rates 
although the latter compound oes not interact 
with PAF receptors [3]. Third, PMN treated with 
pronase, a competitive PAF antagonist (L652731; 
IDso = 30 nM [7]), or excess PAF exhibited 70 to 
nearly 100070 decreases in high- and low-affinity 
receptor numbers. These cells, nevertheless, show- 
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Fig.2. Cellular binding and metabolism of PAF. Where indicated, PMN were pretreated with 860 U/ml pronase for 30 min (G-I) or 
100 nM PAF for 30 min (M-O) at 37°C and then washed twice before accessing binding. These cells retained full viability and bound 
[3H]phorbol myristat¢ acetate normally [6]. Alternatively, PMN were incubated with 500 nM L652731 for 5 min at 4°C (J) or 37°C 
(K,L) before assessing PAF binding and metabolism, respectively. These cells also were fully viable; they responded to and bound 
leukotriene B4 normally [7]. Binding results are corrected for non-specific binding [6] and reported as Scatchard plots from which high- 
affinity (Ka = 0.5-1 nM) binding sites per PMN were extrapolated to be: 12000 in control, 2500 in pronase-pretreated, 900 in 
L652731-pretreated, and - 0 in PAF-pretreated cells. For low-affinity (Kd = 100-400 nM) binding sites, receptor numbers were: 
300000, 80000, 20000, and 170000, respectively. (D) Total uncorrected binding by 2.5 x 107 HL-60 cells/ml at the indicated concen- 
tration of PAF. In metabolic studies, PMN (107/ml) or HL-60 cells (2.5 x 106/ml) were incubated at 37°C for the indicated time with 
63 pM (B,E,H,K,N) or 63 nM PAF (C,F,I,L,O). Results are for the mean of >-6 (binding) or >-4 (metabolism) studies. 
ed no comparable losses in their ability to 
metabolize PAF (fig.2G-O, and legend). We did 
observe that pronase and L652731 decreased by 
< 20°7o and PAF pretreatment i creased by < 30°70 
the rate of PMN metabolism of 6-2000 pM PAF. 
However, the regimens did not influence meta- 
bolism of _ 6 nM PAF (not shown). Thus, PAF 
metabolic apacity and receptor availability were 
clearly dissociable. We therefore suggest that 
mature and immature myelogenous cells can 
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metabolize PAF  and 1-O-alkyl-2-1yso-GPC 
through pathways that do not directly involve PAF  
receptors. 
1-O-Alkyl-2-iyso-GPC enters erythrocytes by a 
receptor-independent route [8]. Furthermore, this 
GPC as well as 1,2-diacyl- and-l-O-alkyl-2-acyl- 
GPC are shuttled intermembranously b cytosolic 
exchange proteins [9712]. Accordingly, we propose 
the following model for GPC processing. Ex- 
ogenous PAF,  1-O-alkyl-2-1yso-GPC, and other 
GPCs  penetrate to the inner leaflet of  the plasma- 
lemma by a diffusional process that may be faci- 
litated by integral membrane proteins [13,14] but 
does not involve specific receptor binding. Inner 
leaflet GPC is metabolized and then transferred to 
Golgi/granules by exchange proteins or, alter- 
natively, associates first with exchange proteins 
and becomes metabolized uring or after trans- 
cytosolic movement. Further study of  this model 
and other possible routes for PAF  metabolism (e.g. 
receptor-independent endocytosis) obviously will 
be required. Regardless of  the exact processing 
pathway used, however, we find that interference 
with PAF  receptors has relatively little influence 
upon myelogenous cell inactivation of  PAF.  PAF  
antagonists, we suggest, may not appreciably in- 
crease the in vivo half-life or toxicity of  PAF  by 
this mechanism. 
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